当前位置： SCI文献检索 > ACS Medicinal Chemistry Letters期刊下所有文献 > Visible-Light Photocatalysis as an Enabling Technology for Drug Discovery: A Paradigm Shift for Chemical Reactivity.

Visible-Light Photocatalysis as an Enabling Technology for Drug Discovery: A Paradigm Shift for Chemical Reactivity.

Abstract：

:Visible light-mediated photocatalysis, which relies on the ability of photocatalysts to absorb low-energy visible light and engage in single-electron transfer (SET) or energy transfer (ET) processes with organic substrates, has emerged as one of the fastest growing fields in organic synthesis. This catalytic platform enables a highly selective approach to promote radical-based organic transformations which unlocks unique reaction pathways. Due to the extremely mild conditions of these transformations and compatibility in aqueous environments, photocatalysis has emerged as an enabling technology in drug discovery. Photocatalysis is uniquely positioned for application in pharmaceutical development because of its demonstrated potential for broad functional group tolerance, biocompatibility, site-specific selectivity, and operational simplicity. This review will highlight the recent advances of visible-light photocatalysis through its application in peptide functionalization, protein bioconjugation, Csp3-Csp2 cross-coupling, late-stage functionalization, isotopic labeling, DNA-encoded library technology (DELT), and microenvironment mapping (μMap).

journal_name

ACS Med Chem Lett

journal_title

ACS medicinal chemistry letters

authors

Li P,Terrett JA,Zbieg JR

doi

10.1021/acsmedchemlett.0c00436

subject

Has Abstract

pub_date

2020-09-21 00:00:00

pages

2120-2130

issue

11

issn

1948-5875

journal_volume

11

pub_type

杂志文章

相关文献

ACS Medicinal Chemistry Letters文献大全
  • Evaluation of a Series of β-Secretase 1 Inhibitors Containing Novel Heteroaryl-Fused-Piperazine Amidine Warheads.

    abstract：:Despite several years of research, only a handful of β-secretase (BACE) 1 inhibitors have entered clinical trials as potential therapeutics against Alzheimer's disease. The intrinsic basic nature of low molecular weight, amidine-containing BACE 1 inhibitors makes them far from optimal as central nervous system drugs. ...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.9b00181

    authors： Oehlrich D,Peschiulli A,Tresadern G,Van Gool M,Vega JA,De Lucas AI,Alonso de Diego SA,Prokopcova H,Austin N,Van Brandt S,Surkyn M,De Cleyn M,Vos A,Rombouts FJR,Macdonald G,Moechars D,Gijsen HJM,Trabanco AA

    更新日期：2019-07-02 00:00:00

  • Synthesis and in vitro and in vivo pharmacological evaluation of new 4-aminoquinoline-based compounds.

    abstract：:A new class of 4-aminoquinolines was synthesized and evaluated in vitro for antiplasmodial activity against both the chloroquine-sensitive (3D7) and -resistant (K1 and W2) strains. The most active compounds 3c-3e had acceptable cytotoxicity but showed strong inhibition toward a panel of cytochrome P450 enzymes in vitr...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml400311r

    authors： Tukulula M,Njoroge M,Abay ET,Mugumbate GC,Wiesner L,Taylor D,Gibhard L,Norman J,Swart KJ,Gut J,Rosenthal PJ,Barteau S,Streckfuss J,Kameni-Tcheudji J,Chibale K

    更新日期：2013-10-01 00:00:00

  • Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140.

    abstract：:This report describes the discovery of RAD140, a potent, orally bioavailable, nonsteroidal selective androgen receptor modulator (SARM). The characterization of RAD140 in several preclinical models of anabolic androgen action is also described. ...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml1002508

    authors： Miller CP,Shomali M,Lyttle CR,O'Dea LS,Herendeen H,Gallacher K,Paquin D,Compton DR,Sahoo B,Kerrigan SA,Burge MS,Nickels M,Green JL,Katzenellenbogen JA,Tchesnokov A,Hattersley G

    更新日期：2010-12-02 00:00:00

  • Dual-Stage Picolinic Acid-Derived Inhibitors of Toxoplasma gondii.

    abstract：:Toxoplasma gondii causes a prevalent human infection for which only the acute stage has an FDA-approved therapy. To find inhibitors of both the acute stage parasites and the persistent cyst stage that causes a chronic infection, we repurposed a compound library containing known inhibitors of parasitic hexokinase, the ...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.0c00267

    authors： Khalifa MM,Martorelli Di Genova B,McAlpine SG,Gallego-Lopez GM,Stevenson DM,Rozema SD,Monaghan NP,Morris JC,Knoll LJ,Golden JE

    更新日期：2020-10-13 00:00:00

  • Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as hsp90 C-terminal inhibitors.

    abstract：:Hsp90 C-terminal inhibitors represent a novel and alternative chemotherapeutic approach for the treatment of cancer. Novobiocin was the first natural product identified as an Hsp90 C-terminal inhibitor; however, it manifests poor antiproliferative activity. In contrast to N-terminal inhibitors, novobiocin does not ind...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml5004475

    authors： Garg G,Zhao H,Blagg BS

    更新日期：2014-12-12 00:00:00

  • Small Molecule that Reverses Dexamethasone Resistance in T-cell Acute Lymphoblastic Leukemia (T-ALL).

    abstract：:Glucocorticoids are one of the most utilized and effective therapies in treating T-cell acute lymphoblastic leukemia. However, patients often develop resistance to glucocorticoids, rendering these therapies ineffective. We screened 9517 compounds, selected for their lead-like properties, chosen from among 3 372 615 co...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml500044g

    authors： Cantley AM,Welsch M,Ambesi-Impiombato A,Sanchez-Martin M,Kim MY,Bauer A,Ferrando A,Stockwell BR

    更新日期：2014-04-25 00:00:00

  • Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation.

    abstract：:We describe the discovery of three structurally differentiated potent and selective MTH1 inhibitors and their subsequent use to investigate MTH1 as an oncology target, culminating in target (in)validation. Tetrahydronaphthyridine 5 was rapidly identified as a highly potent MTH1 inhibitor (IC50 = 0.043 nM). Cocrystalli...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.9b00420

    authors： Farand J,Kropf JE,Blomgren P,Xu J,Schmitt AC,Newby ZE,Wang T,Murakami E,Barauskas O,Sudhamsu J,Feng JY,Niedziela-Majka A,Schultz BE,Schwartz K,Viatchenko-Karpinski S,Kornyeyev D,Kashishian A,Fan P,Chen X,Lansdon EB

    更新日期：2019-11-19 00:00:00

  • Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.

    abstract：:The first allosteric, type III inhibitor of LIM-kinase 2 (LIMK2) is reported. A series of molecules that feature both an N-phenylsulfonamide and tertiary amide were not only very potent at LIMK2 but also were extremely selective against a panel of other kinases. Enzymatic kinetic studies showed these molecules to be n...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml500242y

    authors： Goodwin NC,Cianchetta G,Burgoon HA,Healy J,Mabon R,Strobel ED,Allen J,Wang S,Hamman BD,Rawlins DB

    更新日期：2014-08-07 00:00:00

  • N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation.

    abstract：:A focused multiply N-methylated library of a cyclic hexapeptidic somatostatin analogue: MK678 cyclo(-MeAYwKVF-) was generated, which resulted in the unexpected observation of an efficacious tetra-N-methylated analogue, cyclo(-MeAYMewMeKVMeF-) with a potent inhibitory action on sensory neuropeptide release in vitro and...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml200032v

    authors： Chatterjee J,Laufer B,Beck JG,Helyes Z,Pintér E,Szolcsányi J,Horvath A,Mandl J,Reubi JC,Kéri G,Kessler H

    更新日期：2011-04-04 00:00:00

  • Discovery and Assessment of Atropisomers of (±)-Lesinurad.

    abstract：:(+)- and (-)-Lesinurad were isolated as atropisomers from racemic lesinurad for the first time. No interconversion was observed between the two atropisomers under various conditions tested. The two atropisomers showed significant differences in hURAT1 highly expressed HEK293 cell-based inhibition assays, monkey pharma...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.6b00465

    authors： Wang J,Zeng W,Li S,Shen L,Gu Z,Zhang Y,Li J,Chen S,Jia X

    更新日期：2017-02-14 00:00:00

  • Crown Ether Host-Rotaxanes as Cytotoxic Agents.

    abstract：:Highly toxic bacterial ionophores are commonly used in veterinary medicine, but their therapeutic index is too narrow for human usage. With the goal of developing ionophores with a broader therapeutic index, we constructed highly derivatized synthetic ionophores. The toxicities of crown ether host-rotaxanes (CEHR's) a...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml3003204

    authors： Smithrud DB,Wang X,Tarapore P,Ho SM

    更新日期：2013-01-10 00:00:00

  • Benzoxaboroles: New Potent Inhibitors of the Carbonic Anhydrases of the Pathogenic Bacterium Vibrio cholerae.

    abstract：:A series of urea/thiourea substituted benzoxaboroles was investigated for the inhibition of the three carbonic anhydrases encoded by Vibrio cholerae (VchCAα, VchCAβ, and VchCAγ). In particular, benzoxaborole derivatives were here first assayed for the inhibition of a γ-class CA, extending the panel of CA classes that ...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.0c00403

    authors： Bonardi A,Nocentini A,Cadoni R,Del Prete S,Dumy P,Capasso C,Gratteri P,Supuran CT,Winum JY

    更新日期：2020-09-09 00:00:00

  • Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.

    abstract：:We report the discovery of a new (S)-3-aminopyrrolidine series of CCR2 antagonists. Structure-activity relationship studies on this new series led to the identification of 17 (INCB8761/PF-4136309) that exhibited potent CCR2 antagonistic activity, high selectivity, weak hERG activity, and an excellent in vitro and in v...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml200199c

    authors： Xue CB,Wang A,Han Q,Zhang Y,Cao G,Feng H,Huang T,Zheng C,Xia M,Zhang K,Kong L,Glenn J,Anand R,Meloni D,Robinson DJ,Shao L,Storace L,Li M,Hughes RO,Devraj R,Morton PA,Rogier DJ,Covington M,Scherle P,Diamond

    更新日期：2011-10-05 00:00:00

  • Aminopyridyl/Pyrazinyl Spiro[indoline-3,4'-piperidine]-2-ones As Highly Selective and Efficacious c-Met/ALK Inhibitors.

    abstract：:A series of novel aminopyridyl/pyrazinyl-substituted spiro[indoline-3,4'-piperidine]-2-ones were designed, synthesized, and tested in various in vitro/in vivo pharmacological and antitumor assays. 6-[6-Amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-3-pyridyl]-1'-methylspiro[indoline-3,4'-piperidine]-2-one (compo...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml400203d

    authors： Li J,Wu N,Tian Y,Zhang J,Wu S

    更新日期：2013-07-12 00:00:00

  • Salinomycin Hydroxamic Acids: Synthesis, Structure, and Biological Activity of Polyether Ionophore Hybrids.

    abstract：:The polyether ionophore salinomycin has recently gained attention due to its exceptional ability to selectively reduce the proportion of cancer stem cells within a number of cancer cell lines. Efficient single step strategies for the preparation of hydroxamic acid hybrids of this compound varying in N- and O-alkylatio...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.6b00079

    authors： Borgström B,Huang X,Chygorin E,Oredsson S,Strand D

    更新日期：2016-04-25 00:00:00

  • Discovery of Novel Putative Inhibitors of UDP-GlcNAc 2-Epimerase as Potent Antibacterial Agents.

    abstract：:We present the discovery and optimization of a novel series of inhibitors of bacterial UDP-N-acetylglucosamine 2-epimerase (called 2-epimerase in this paper). Starting from virtual screening hits, the activity of various inhibitory molecules was optimized using a combination of structure-based and rational design appr...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml4001936

    authors： Xu Y,Brenning B,Clifford A,Vollmer D,Bearss J,Jones C,McCarthy V,Shi C,Wolfe B,Aavula B,Warner S,Bearss DJ,McCullar MV,Schuch R,Pelzek A,Bhaskaran SS,Stebbins CE,Goldberg AR,Fischetti VA,Vankayalapati H

    更新日期：2013-12-12 00:00:00

  • Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease.

    abstract：:A new series of potent TG2 inhibitors are reported that employ a 4-aminopiperidine core bearing an acrylamide warhead. We establish the structure-activity relationship of this new series and report on the transglutaminase selectivity and in vitro ADME properties of selected compounds. We demonstrate that the compounds...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml3001352

    authors： Prime ME,Brookfield FA,Courtney SM,Gaines S,Marston RW,Ichihara O,Li M,Vaidya D,Williams H,Pedret-Dunn A,Reed L,Schaertl S,Toledo-Sherman L,Beconi M,Macdonald D,Muñoz-Sanjuan I,Dominguez C,Wityak J

    更新日期：2012-08-09 00:00:00

  • Identification of New Nonsteroidal RORα Ligands; Related Structure-Activity Relationships and Docking Studies.

    abstract：:A high throughput screen was developed to identify novel, nonsteroidal RORα agonists. Among the validated hit compounds, the 4-(4-(benzyloxy)phenyl)-5-carbonyl-2-oxo-1,2,3,4-tetrahydropyrimidine scaffold was the most prominent. Among the numerous analogues tested, compounds 8 and 9 showed the highest activity. Key str...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml300471d

    authors： Dubernet M,Duguet N,Colliandre L,Berini C,Helleboid S,Bourotte M,Daillet M,Maingot L,Daix S,Delhomel JF,Morin-Allory L,Routier S,Walczak R

    更新日期：2013-04-10 00:00:00

  • Optimization of an albumin-binding prodrug of Doxorubicin that is cleaved by prostate-specific antigen.

    abstract：:We have developed a novel albumin-binding prodrug of doxorubicin that incorporates p-aminobenzyloxycarbonyl (PABC) as a 1,6 self-immolative spacer in addition to the heptapeptide, Arg-Ser-Ser-Tyr-Tyr-Ser-Leu, as a substrate for the prostate-specific antigen (PSA) that is overexpressed in prostate carcinoma and represe...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml100060m

    authors： Elsadek B,Graeser R,Warnecke A,Unger C,Saleem T,El-Melegy N,Madkor H,Kratz F

    更新日期：2010-05-26 00:00:00

  • Synthetic and Immunological Studies of sTn Derivatives Carrying 5-N-(p-Substituted Phenylacetyl)Sialic Acid for the Development of Effective Cancer Vaccines.

    abstract：:To search for effective cancer vaccines based on sTn, a sialylated tumor-associated carbohydrate antigen (sialo-TACA) expressed by a number of tumors, four unnatural N-acyl sTn derivatives, including 5'-N-p-methylphenylacetyl sTn (sTnNMePhAc), 5'-N-p-methoxylphenylacetyl sTn (sTnNMeOPhAc), 5'-N-p-acetylphenylacetyl sT...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml100313d

    authors： Wang Q,Guo Z

    更新日期：2011-05-12 00:00:00

  • Augmenting the Activity of Macrolide Adjuvants against Acinetobacter baumannii.

    abstract：:Approximately 1.7 million Americans develop hospital associated infections each year, resulting in more than 98,000 deaths. One of the main contributors to such infections is the Gram-negative pathogen Acinetobacter baumannii. Recently, it was reported that aryl 2-aminoimidazole (2-AI) compounds potentiate macrolide a...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.0c00276

    authors： Hubble VB,Bartholomew KR,Weig AW,Brackett SM,Barlock SL,Mattingly AE,Nemeth AM,Melander RJ,Melander C

    更新日期：2020-08-12 00:00:00

  • BOPC1 Enantiomers Preparation and HuR Interaction Study. From Molecular Modeling to a Curious DEEP-STD NMR Application.

    abstract：:The Hu family of RNA-binding proteins plays a crucial role in post-transcriptional processes; indeed, Hu-RNA complexes are involved in various dysfunctions (i.e., inflammation, neurodegeneration, and cancer) and have been recently proposed as promising therapeutic targets. Intrigued by this concept, our research effor...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.9b00659

    authors： Volpe SD,Listro R,Parafioriti M,Di Giacomo M,Rossi D,Ambrosio FA,Costa G,Alcaro S,Ortuso F,Hirsch AKH,Vasile F,Collina S

    更新日期：2020-01-28 00:00:00

  • Synthesis and Evaluation of Noviose Replacements on Novobiocin that Manifest Anti-proliferative Activity.

    abstract：:Structural modifications to the coumarin core and benzamide side chain of novobiocin have successfully transformed the natural product from a selective DNA gyrase inhibitor into a potent inhibitor of the Hsp90 C-terminus. However, no SAR studies have been conducted on the noviose appendage, which represents the rate-l...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml100070r

    authors： Zhao H,Kusuma BR,Blagg BS

    更新日期：2010-07-13 00:00:00

  • Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist.

    abstract：:Incorporation of polar functionality into a series of highly potent calcitonin gene-related peptide (CGRP) receptor antagonists was explored in an effort to improve pharmacokinetics. This strategy identified piperazinone analogues that possessed improved solubility at acidic pH and increased oral bioavailability in mo...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml900016y

    authors： Bell IM,Gallicchio SN,Wood MR,Quigley AG,Stump CA,Zartman CB,Fay JF,Li CC,Lynch JJ,Moore EL,Mosser SD,Prueksaritanont T,Regan CP,Roller S,Salvatore CA,Kane SA,Vacca JP,Selnick HG

    更新日期：2010-01-12 00:00:00

  • Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.

    abstract：:A novel peroxisome proliferator-activated receptor (PPAR) α/δ dual agonist 5c was developed with an EC50 of 8 nM for PPARα, 5 nM for PPARδ, and >300-fold selectivity against PPARγ (EC50 = 2939 nM), respectively. Further ADME and pharmacokinetic studies indicated 5c possessed distinguished in vitro and in vivo profiles...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.9b00189

    authors： Jiang Z,Liu X,Yuan Z,He H,Wang J,Zhang X,Gong Z,Hou L,Shen L,Guo F,Zhang J,Wang J,Xu D,Liu Z,Li H,Chen X,Long C,Li J,Chen S

    更新日期：2019-06-24 00:00:00

  • Structure-Metabolism Relationships in the Glucuronidation of d-Amino Acid Oxidase Inhibitors.

    abstract：:Representative d-amino acid oxidase (DAAO) inhibitors were subjected to in vitro liver microsomal stability tests in the absence or presence of uridine diphosphate glucuronic acid (UDPGA). While carboxylate-based DAAO inhibitors displayed little glucuronidation, most DAAO inhibitors containing α-hydroxycarbonyl moiety...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml500335z

    authors： Zimmermann SC,Rais R,Alt J,Burzynski C,Slusher BS,Tsukamoto T

    更新日期：2014-10-21 00:00:00

  • A new challenging and promising era of tyrosine kinase inhibitors.

    abstract：:Protein kinases are key regulators that govern complex cellular processes. Dysregulation of kinase signaling is associated in many human diseases, particularly cancers and developmental and metabolic disorders. Tyrosine kinase inhibitors have achieved great success in molecular targeted therapies for cancer and now is...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/ml500091p

    authors： Cui JJ

    更新日期：2014-03-06 00:00:00

  • Homogeneous Assay for Target Engagement Utilizing Bioluminescent Thermal Shift.

    abstract：:Protein thermal shift assays (TSAs) provide a means for characterizing target engagement through ligand-induced thermal stabilization. Although these assays are widely utilized for screening libraries and validating hits in drug discovery programs, they can impose encumbering operational requirements, such as the avai...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.8b00081

    authors： Dart ML,Machleidt T,Jost E,Schwinn MK,Robers MB,Shi C,Kirkland TA,Killoran MP,Wilkinson JM,Hartnett JR,Zimmerman K,Wood KV

    更新日期：2018-04-16 00:00:00

  • Dipeptidyl Nitroalkenes as Potent Reversible Inhibitors of Cysteine Proteases Rhodesain and Cruzain.

    abstract：:Dipeptidyl nitroalkenes are potent reversible inhibitors of cysteine proteases. Inhibitor 11 resulted to be the most potent one with Ki values of 0.49 and 0.44 nM against rhodesain and cruzain, respectively. According to enzymatic dilution and dialysis experiments, as well as computational and NMR studies, dipeptidyl ...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.6b00276

    authors： Latorre A,Schirmeister T,Kesselring J,Jung S,Johé P,Hellmich UA,Heilos A,Engels B,Krauth-Siegel RL,Dirdjaja N,Bou-Iserte L,Rodríguez S,González FV

    更新日期：2016-09-21 00:00:00

  • Chalcones and Chalcone-mimetic Derivatives as Notch Inhibitors in a Model of T-cell Acute Lymphoblastic Leukemia.

    abstract：:Based on hit-likeness and chemical diversity, a number of chalcones and chalcone-mimetic compounds were selected as putative Notch inhibitors. The evaluation of the antiproliferative effect combined with the inhibition of Notch1 expression in KOPTK1 cell line identified compound 18, featuring a tetrahydronaphthalene-b...

    journal_title：ACS medicinal chemistry letters

    pub_type： 杂志文章

    doi：10.1021/acsmedchemlett.8b00608

    authors： Quaglio D,Zhdanovskaya N,Tobajas G,Cuartas V,Balducci S,Christodoulou MS,Fabrizi G,Gargantilla M,Priego EM,Carmona Pestaña Á,Passarella D,Screpanti I,Botta B,Palermo R,Mori M,Ghirga F,Pérez-Pérez MJ

    更新日期：2019-02-26 00:00:00